$26.21
0.00% today
Nasdaq, Sep 24, 03:48 pm CET

Pacira Pharmaceuticals, Inc. Stock price

$26.21
+0.85 3.35% 1M
+1.37 5.52% 6M
+7.37 39.12% YTD
+11.93 83.54% 1Y
-26.65 50.42% 3Y
-32.73 55.53% 5Y
-29.78 53.19% 10Y
+19.19 273.36% 20Y
Nasdaq, Closing price Tue, Sep 23 2025
-0.25 0.94%

Key metrics

Basic
Market capitalization
$1.2b
Enterprise Value
$1.3b
Net debt
$134.6m
Cash
$445.9m
Shares outstanding
44.9m
Valuation (TTM | estimate)
P/E
negative | 9.1
P/S
1.7 | 1.6
EV/Sales
1.9 | 1.7
EV/FCF
11.2
P/B
1.6
Financial Health
Equity Ratio
50.1%
Return on Equity
-12.8%
ROCE
5.7%
ROIC
-
Debt/Equity
0.8
Financials (TTM | estimate)
Revenue
$705.9m | $752.6m
EBITDA
$127.2m | $209.0m
EBIT
$69.9m | $110.6m
Net Income
$-127.5m | $129.8m
Free Cash Flow
$117.1m
Growth (TTM | estimate)
Revenue
-17.7% | 7.4%
EBITDA
-32.3% | 35.0%
EBIT
-39.9% | 13.3%
Net Income
-275.5% | 230.4%
Free Cash Flow
-36.7%
Margin (TTM | estimate)
Gross
78.2%
EBITDA
18.0% | 27.8%
EBIT
9.9%
Net
-18.1% | 17.3%
Free Cash Flow
16.6%
More
EPS
$-2.8
FCF per Share
$2.6
Short interest
21.1%
Employees
789
Rev per Employee
$890.0k
Show more

Is Pacira Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

Pacira Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Pacira Pharmaceuticals, Inc. forecast:

9x Buy
69%
3x Hold
23%
1x Sell
8%

Analyst Opinions

13 Analysts have issued a Pacira Pharmaceuticals, Inc. forecast:

Buy
69%
Hold
23%
Sell
8%

Financial data from Pacira Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
706 706
18% 18%
100%
- Direct Costs 154 154
32% 32%
22%
552 552
13% 13%
78%
- Selling and Administrative Expenses 329 329
5% 5%
47%
- Research and Development Expense 95 95
2% 2%
14%
127 127
32% 32%
18%
- Depreciation and Amortization 57 57
20% 20%
8%
EBIT (Operating Income) EBIT 70 70
40% 40%
10%
Net Profit -127 -127
276% 276%
-18%

In millions USD.

Don't miss a Thing! We will send you all news about Pacira Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Pacira Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
19 days ago
BRISBANE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on September 3, 2025 to nine new employees under Pacira's Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material in...
Neutral
The Motley Fool
about 2 months ago
Pacira BioSciences (PCRX -1.74%) is a specialty pharmaceutical company known for its non-opioid pain management products. On August 5, 2025, it reported financial results for the quarter. The headline results showed non-GAAP earnings per share of $0.74, beating analyst consensus by 4.2% (non-GAAP), while revenue (GAAP) came in at $181.1 million, missing GAAP revenue expectations by 1.1%. Compar...
Neutral
Seeking Alpha
about 2 months ago
Pacira BioSciences, Inc. (NASDAQ:PCRX ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Brendan P. Teehan - Chief Commercial Officer Frank D.
More Pacira Pharmaceuticals, Inc. News

Company Profile

Pacira Biosciences, Inc. develops and manufactures injectable therapeutic products. The firm engages in the development, commercialization and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ.

Head office United States
CEO Frank Lee
Employees 789
Founded 2006
Website www.pacira.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today